Phase 2 Clinical Trial of Crizotinib for Children and Adults With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas

PHASE2CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

February 18, 2020

Primary Completion Date

February 25, 2025

Study Completion Date

February 25, 2025

Conditions
Neurofibromatosis 2Progressive Vestibular Schwannoma (VS)
Interventions
DRUG

Crizotinib

Oral

Trial Locations (15)

10016

New York University Medical Center (Site 200), New York

10065

Memorial Sloan Kettering Cancer Center (Site 210), New York

19096

Children's Hospital of Philadelphia (Site 750), Philadelphia

20010

Children's National Medical Center (Site 775), Washington D.C.

21287

Johns Hopkins University (Site 250), Baltimore

30324

Children's HealthCare of Atlanta (Site 950), Atlanta

35294

The University of Alabama at Birmingham (Site 700), Birmingham

46202

Indiana University (Site 400), Indianapolis

60611

Lurie Childrens Hospital of Chicago (Site 350), Chicago

60637

University of Chicago (Site 850), Chicago

63110

Washington University - St. Louis (Site 900), St Louis

75235

Childrens Medical Center - Univ. of Texas SW (Site 917), Dallas

90027

Univ of California @ Los Angeles (Site 325), Los Angeles

02115

Children's Hospital Boston (Site 725), Boston

45229-3039

Cincinnati Children's Hospital Medical Center (Site 800), Cincinnati

All Listed Sponsors
collaborator

Memorial Sloan Kettering Cancer Center

OTHER

collaborator

Children's Hospital of Philadelphia

OTHER

lead

University of Alabama at Birmingham

OTHER

NCT04283669 - Phase 2 Clinical Trial of Crizotinib for Children and Adults With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas | Biotech Hunter | Biotech Hunter